growth hormone releasing peptide

Growth hormone releasing peptide ia a natual product ,and has anti-inflammatory effects, due to its inhibitory effect on PKC-induced activation of p38, JNK and NF-κB, possibly by targeting to MKP-1 and PP2A.

Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

KARI 201 hydrochloride is a selective, brain-penetrant, competitive inhibitor of acid sphingomyelinase (ASM) with an IC50 of 338.3 nM. It also acts as an agonist for the growth hormone-releasing peptide receptor (ghrelin receptor). Additionally, KARI 201 hydrochloride can enhance the neuropathological features of Alzheimer's disease.

Somatorelin (1-44) amide is a synthetic peptide that corresponds to the full 44-amino acid sequence of growth hormone-releasing hormone (GHRH), a hormone that stimulates the production of growth hormone from the pituitary gland and is involved in the regulation of cell proliferation and differentiation.1,2Somatorelin induces growth hormone release similarly to GHRHin vitroandin vivo.1

GHRF, porcine, a growth hormone releasing factor (GHRF) peptide (porcine), binds to the growth hormone secretagogue receptor (GHSR), thereby inducing the release of growth hormone [1] [2].

[D-p-Cl-Phe6,Leu17]-VIP TFA acts as a competitive and selective antagonist of the vasoactive intestinal peptide (VIP) receptor, with an IC50 of 125.8 nM, and shows no activity on glucagon, secretin, or growth hormone-releasing factor (GRF) receptors [1] [2] [3].

Ipamorelin (NNC-26-0161) is a growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Ipamorelin 2 Pivalic acid (NNC-26-0161) is a growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, a growth hormone releasing peptide and metabolite of GHRP-1 (Ala-His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2), stimulates growth hormone (GH) secretion and elevates intracellular calcium concentration ([Ca2+]i) in rat pituitary gland monolayer cells without altering cAMP levels [1].

LEAP-2 (Human liver expressed antimicrobial peptide-2) is an antimicrobial peptide and an endogenous competitive antagonist of growth hormone-releasing peptide, as well as a reverse agonist of constitutive GHS-R1a activity, used for research on obesity and other metabolic diseases.

GHRF (mouse), a mouse growth hormone-releasing factor, is a 44-amino acid peptide that promotes the synthesis and release of growth hormone [1].

Relugolix-D6 is a deuterated compound of Relugolix. Relugolix (T3630) has a CAS number of 737789-87-6. Relugolix (T3630) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix (T3630) competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Relugolix (Standard) is a reference standard for research and analysis in studies involving Relugolix. Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Relugolix-D6 (Standard) is a reference standard of Relugolix-D6 intended for quantitative analysis, quality control, and related biochemical research applications. Relugolix-d6 is a deuterated compound of Relugolix. Relugolix has a CAS number of 737789-87-6. Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Cortistatin-14, a neuropeptide structurally similar to growth inhibitor-14, has anticonvulsant and neuroprotective effects and impairs recognition memory consolidation in mice through activation of sst(2), growth hormone-releasing peptide, and GABA(A/B) receptor, which can be used to study sepsis-induced cognitive impairment.

Cortistatin-8 acetate is a corticosteroid analog, a GHS-R antagonist with inhibitory effects on the growth hormone pro-secretin receptor.Cortistatin-8 acetate is a synthetic corticosteroid-derived ligand for the growth hormone-releasing peptide receptor and does not alter the endocrine response to acylated growth hormone-releasing peptide or hesperidin in humans.Cortistatin-8 acetate is a synthetic corticosteroid-derived ligand for the growth hormone-releasing peptide receptor.

GHRF, mouse TFA is a peptide consisting of 44 amino acids that serves as a growth hormone-releasing factor in mice. This compound stimulates both the release and synthesis of growth hormone.